• Keith G Rasmussen, Simon Kung, Maria I Lapid, Tyler S Oesterle, Jennifer R Geske, Gregory A Nuttall, William C Oliver, and John P Abenstein.
• Mayo Clinic Departments of Psychiatry and Psychology, Rochester, MN 55905, USA. Electronic address: rasmussen.keith@mayo.edu.
• Psychiatry Res. 2014 Feb 28; 215 (2): 362-5.

AbstractTo assess the clinical utility of ketamine as an anesthetic agent for electroconvulsive therapy (ECT), based upon recent findings that ketamine may have antidepressant properties. Depressed ECT patients were randomly assigned to receive anesthesia with either ketamine or methohexital. Outcome measures included assessments of depressive severity, cognition, post-anesthesia side effects, and hemodynamics. Twenty one patients were treated with ketamine and 17 with methohexital. There were no significant differences in depression or cognitive outcomes between the two drugs. Additionally, there were no measures of post-anesthesia tolerability or hemodynamics which favored ketamine. Ketamine anesthesia does not accelerate the antidepressant effect of ECT or diminish the cognitive side effects, at least as measured in this study. Furthermore, there is no apparent benefit of ketamine for speed or quality of post-ECT recovery, and it is associated with higher systolic blood pressures after the treatments. Ketamine is associated with longer motor seizure duration than methohexital.Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

32 keywords...

hide…